ProfileGDS5678 / 1436014_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 61% 58% 62% 63% 57% 59% 58% 58% 58% 61% 63% 61% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6407760
GSM967853U87-EV human glioblastoma xenograft - Control 23.6433461
GSM967854U87-EV human glioblastoma xenograft - Control 33.5092958
GSM967855U87-EV human glioblastoma xenograft - Control 43.6776862
GSM967856U87-EV human glioblastoma xenograft - Control 53.7027463
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5650557
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6435259
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5037458
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4635958
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4832458
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6311661
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7232763
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6385961
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.814164